Soo Youn Bae1, Sei Joong Kim2, JungSun Lee3, Eun Sook Lee4, Eun-Kyu Kim5, Ho Young Park6, Young Jin Suh7, Hong Kyu Kim1, Ji-Young You1, Seung Pil Jung8,9. 1. Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea. 2. Department of Surgery, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea. 3. Department of Surgery, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Republic of Korea. 4. Center for Breast Cancer, National Cancer Center, Goyang-si, Republic of Korea. 5. Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi, Republic of Korea. 6. Department of Surgery, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Daegu, Republic of Korea. 7. Division of Breast & Thyroid Surgical Oncology, Department of Surgery, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Republic of Korea. 8. Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea. jungspil@korea.ac.kr. 9. Division of Breast and Endocrine Surgery, Department of Surgery, Korea University Hospital, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea. jungspil@korea.ac.kr.
Abstract
PURPOSE: We analyzed the clinicopathologic characteristics and prognosis of pregnancy-associated breast cancer (PABC) according to clinical subtypes to better understand the characteristics of PABC. METHODS: A total of 83,792 female patients between the ages of 20 and 49 were enrolled in the Korean Breast Cancer Society Registry database from January 1, 1996 to December 31, 2015. 'PABC' is defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Other patients were defined as 'non-PABC' patients. RESULTS: In non-PABC patients, luminal A subtype was the most common (50.2%). In PABC patients, TNBC was the most common (40.4%) subtype, while luminal A comprised 21.2% and HER2 subtype comprised 17.3%. There was a significant difference in overall survival (OS). In non-PABC patients, TNBC had the highest HR (HR 2.3, 95% CI 2.1-2.6). In PABC patients, the luminal B subtype (HR+ HER2-high Ki67) had the highest HR at 7.0 (95% CI 1.7-29.1). In multivariate analysis of OS by subtypes, PABC patients had significantly higher HR than non-PABC patients in the HER2 subtype (HR 2.0, 95% CI 1.1-3.7) and luminal B subtype (HR+ HER2-high Ki67) (HR 4.4, 95% CI 1.6-12.3). CONCLUSION: PABC showed different biologic features than non-PABC. PABC had a particularly poor prognosis in the luminal B (HR+ HER2-highKi67) and HER2 subtypes. To improve the prognosis of PABC, treatment should be considered according to subtype. Development of drugs that can be used during pregnancy is needed.
PURPOSE: We analyzed the clinicopathologic characteristics and prognosis of pregnancy-associated breast cancer (PABC) according to clinical subtypes to better understand the characteristics of PABC. METHODS: A total of 83,792 female patients between the ages of 20 and 49 were enrolled in the Korean Breast Cancer Society Registry database from January 1, 1996 to December 31, 2015. 'PABC' is defined as breast cancer diagnosed during pregnancy or within 1 year after delivery. Other patients were defined as 'non-PABC' patients. RESULTS: In non-PABCpatients, luminal A subtype was the most common (50.2%). In PABCpatients, TNBC was the most common (40.4%) subtype, while luminal A comprised 21.2% and HER2 subtype comprised 17.3%. There was a significant difference in overall survival (OS). In non-PABCpatients, TNBC had the highest HR (HR 2.3, 95% CI 2.1-2.6). In PABCpatients, the luminal B subtype (HR+ HER2-high Ki67) had the highest HR at 7.0 (95% CI 1.7-29.1). In multivariate analysis of OS by subtypes, PABCpatients had significantly higher HR than non-PABCpatients in the HER2 subtype (HR 2.0, 95% CI 1.1-3.7) and luminal B subtype (HR+ HER2-high Ki67) (HR 4.4, 95% CI 1.6-12.3). CONCLUSION:PABC showed different biologic features than non-PABC. PABC had a particularly poor prognosis in the luminal B (HR+ HER2-highKi67) and HER2 subtypes. To improve the prognosis of PABC, treatment should be considered according to subtype. Development of drugs that can be used during pregnancy is needed.
Entities:
Keywords:
Breast cancer; Pregnancy; Prognosis; Subtype
Authors: B B M Suelmann; A Rademaker; C van Dooijeweert; E van der Wall; P J van Diest; C B Moelans Journal: Cell Oncol (Dordr) Date: 2022-07-06 Impact factor: 7.051